EPAS1 (Endothelial PAS Domain Protein 1), also known as HIF-2α (Hypoxia-Inducible Factor 2 alpha) or HLF (HIF-Like Factor), is a transcription factor that serves as the master regulator of cellular responses to hypoxia. Encoded by the EPAS1 gene located on chromosome 2p21, this protein plays critical roles in oxygen homeostasis, angiogenesis, erythropoiesis, and metabolic adaptation. EPAS1 has emerged as a significant player in neurodegenerative disease pathogenesis, particularly through its dysregulation in Alzheimer's disease and Parkinson's disease. [1]
| Property | Value |
|---|---|
| Gene Symbol | EPAS1 |
| Full Name | Endothelial PAS Domain Protein 1 |
| Alternative Names | HIF-2α, HLF, MOP2, bHLHe73 |
| Chromosomal Location | 2p21 |
| NCBI Gene ID | 2034 |
| OMIM ID | 603349 |
| Ensembl ID | ENSG00000177640 |
| UniProt ID | Q9Y5Q3 |
| Associated Diseases | Alzheimer's disease, Parkinson's disease, stroke, vascular cognitive impairment |
The EPAS1 gene spans approximately 90 kb and consists of 16 exons encoding an 870-amino acid protein. The gene exhibits tissue-specific expression patterns with highest levels in endothelial cells, kidney, and certain brain regions.
EPAS1 is a member of the bHLH-PAS (basic Helix-Loop-Helix-Period-Arnt-Sim) transcription factor family. The protein contains several functional domains:
EPAS1/HIF-2α performs several essential cellular functions:
Hypoxia Response: As a heterodimer with HIF-1β (ARNT), EPAS1 binds to hypoxia response elements (HREs) in target gene promoters, activating transcription of:
Angiogenesis Regulation: EPAS1 is a key regulator of blood vessel formation through VEGF and other angiogenic factor regulation.
Erythropoiesis: Controls red blood cell production via EPO regulation.
Metabolic Adaptation: Coordinates cellular metabolic shifts from oxidative phosphorylation to glycolysis under hypoxic conditions.
Stem Cell Maintenance: EPAS1 plays roles in maintaining neural stem cells and progenitor populations.
EPAS1 exhibits tissue-specific expression:
| Tissue/Cell Type | Expression Level |
|---|---|
| Endothelial cells (vascular) | Highest |
| Kidney (medulla and cortex) | High |
| Liver | Moderate-high |
| Heart and skeletal muscle | Moderate |
| Brain (neurons, astrocytes, microglia) | Moderate |
| Carotid body | Very high (oxygen sensing) |
In the central nervous system, EPAS1 is expressed in:
Under normal oxygen conditions:
Under hypoxic conditions:
EPAS1/HIF-2α is implicated in Alzheimer's disease through multiple mechanisms:
AD is characterized by neurovascular unit dysfunction:
Recent research has explored HIF-2α modulation as a therapeutic approach:
EPAS1 involvement in Parkinson's disease includes:
EPAS1 plays complex roles in cerebral ischemia:
EPAS1 contributes to vascular dementia through:
EPAS1 interacts with numerous proteins relevant to neurodegeneration:
| Interaction Partner | Function |
|---|---|
| HIF-1β (ARNT) | Dimerization partner for DNA binding |
| VHL | E3 ligase for degradation under normoxia |
| PHD1/2/3 | Oxygen sensors for hydroxylation |
| p300/CBP | Transcriptional coactivators |
| VEGF | Target gene and angiogenic factor |
| EPO | Target gene for erythropoiesis |
| STAT3 | Cross-talk in inflammation |
| NF-κB | Interaction in inflammatory responses |
| p53 | Cross-talk in stress responses |
Several therapeutic strategies are being explored:
| Approach | Mechanism | Status |
|---|---|---|
| PHD inhibitors | Stabilize HIF including EPAS1 | Approved for anemia, studying in CNS |
| Selective HIF-2α agonists | Direct EPAS1 activation | Preclinical |
| HIF-2α antagonists | Inhibit EPAS1 activity | Research for certain cancers |
| Gene therapy | Modulate EPAS1 expression | Experimental |
| Small molecule modulators | Fine-tune EPAS1 activity | Discovery |
Multiple models have advanced understanding of EPAS1 in neurodegeneration:
Zhang P, et al. Hypoxia-inducible factor 2alpha plays a critical role in the development of alpha-synuclein toxicity in models of Parkinson disease. 2008. ↩︎ ↩︎
Wang et al. Targeting HIF-2alpha therapy in Alzheimer's disease. 2024. ↩︎
Gupta et al. EPAS1 variants and neuroprotection in ischemia. 2023. ↩︎
Bartlett et al. Hypoxia and neurodegenerative diseases. 2021. ↩︎
Chouchane et al. HIF-2alpha regulates Alzheimer-associated genes in models of Parkinson's disease. 2019. ↩︎
Liu Y, et al. Association between EPAS1 gene polymorphisms and Alzheimer's disease in Chinese Han population. 2019. ↩︎